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RadiodermatitisPurpose: To determine if the severity of radiodermatitis at the end of radio(chemo)therapy (R(C)T) for
head and neck cancer (HNC) is a predictive factor for late fibrosis of the neck and to find a model to pre-
dict neck fibrosis gradeP 2 (fibrosis RTOG2-4) at 6 months following R(C)T for HNC.
Material/methods: 161 patients were prospectively included. We correlated radiodermatitis at the end of
RCT, age, sex, T/N stage, tumor site, concomitant chemotherapy, upfront neck dissection, neo-adjuvant
chemotherapy, accelerated RT, smoking, alcohol consumption, HPV status and the dose prescribed to
the elective neck with fibrosis RTOG2-4 6 months after the end of treatment.
Results: Radiodermatitis at the end of R(C)TPgrade 3 proved to be associated with the incidence of fibro-
sis RTOG2-4 at 6 months (p < 0.01). Furthermore, upfront neck dissection (p < 0.01), increasing N stage
(p < 0.01) and tumor site (p = 0.02) are significantly associated in univariate analysis with fibrosis
RTOG2-4 at 6 months of follow-up.
Upfront neck dissection and radiodermatitis gradeP 3 at the end of R(C)T were identified by our multi-
variate model. Additionally, increasing N stage was selected as an independent predictor variable. The
AUC for this model was 0.92.
Conclusion: A model for the prediction of fibrosis RTOG2-4 following R(C)T for head and neck cancer is
presented with an AUC of 0.92. Interestingly, radiodermatitis gradeP 3 at the end of R(C)T is associated
with RTOG2-4 fibrosis at 6 months.
 2016 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology xxx (2016) xxx–xxxRadiotherapy (RT) for head and neck cancer (HNC) has signifi-
cantly changed over the past decades. Treatment intensification
improved clinical outcome, but also increased both early and late
toxicity, heavily compromising Quality of Life (QoL) of the surviv-
ing HNC patients [1–5]. Neck fibrosis by example is an important
late complication following radio(chemo-)therapy (R(C)T) for
HNC [6–8].
Several techniques have been used to treat fibrosis within the
head and neck region, including lycopene, pentoxifylline, pir-
fenidone, vitamin E, aloe vera, corticosteroid injections, interferon
gamma, hyperbaric oxygen, stretching exercises, prophylactic
swallowing exercises, hyperthermia, impedance controlled
microcurrent therapy and acupuncture [9]. However, none of these
techniques have shown a clear benefit up to now [9]. Since the
treatment options for fibrosis following RT for HNC are limited,
we must currently focus on prevention. Therefore it is important
to identify which patient and treatment related parameters areassociated with late fibrosis to select patients at risk for fibrosis
in order to apply prophylactic interventions. Furthermore, using
these parameters, we might be able to select patients for studies
that further investigate potential treatments for fibrosis following
RT for HNC in the future.
The purpose of this study was therefore to identify these
parameters and to build a multivariate model to predict neck fibro-
sis gradeP 2 (fibrosis RTOG2-4) at 6 months following R(C)T for
HNC.Material/methods
Patient and treatment characteristics
The current paper is a second analysis of a prospective random-
ized controlled trial on dose de-escalation to the elective nodal vol-
ume in head and neck cancer. We collected prospectively gathered
data from all 193 patients from this initial trial [10]. Inclusion
criteria from the original trial were previously untreated,
histologically proven squamous cell carcinoma of the oral cavity,devel-
Table 1
Pre-treatment characteristics of the patients cohort.
Patients and treatment characteristics
Upfront neck dissection (ND)
No ND 127/161 (78.9%)
ND 34/161 (21.1%)
Concomitant chemotherapy
No chemotherapy 48/161 (29.8%)
Cisplatinum 113/161 (70.2%)
Neo-adjuvant chemotherapy
No neo-adjuvant chemotherapy 155/161 (96.3%)
Neo-adjuvant chemotherapy 6/161 (3.7%)
Smoking
Never/former 88/160x (55.0%)
Current 72/160x (45.0%)
Alcohol use of more than 3 units a day
Never 13/160x (8.1%)
Former 36/160x (22.5%)
Current 111/160x (69.4%)
T-stage
1 3/161 (1.9%)
2 59/161 (36.7%)
3 55/161 (34.2%)
4 36/161 (22.4%)
0 8/161 (5.0%)
N-stage
0 40/161 (24.8%)
1 23/161 (14.3%)
2a 6/161 (3.7%)
2b 55/161 (34.2%)
2 A predictive model for fibrosis in head and neck canceroropharynx, hypopharynx, larynx or cervical lymph node metas-
tases of unknown primary cancer (CUP). Patient work-up was done
according to institutional guidelines. T1–T2N0 were allowed, if
prophylactic neck irradiation was performed. Patients were older
than 18 years with a Karnofsky performance status P70%. The
decision for primary R(C)T with curative intent had to be made
after a multidisciplinary meeting at each participating center. Con-
current chemotherapy was allowed, as well as pretreatment lymph
node dissection. Local ethics committee approval was obtained
before start of the study and all patients gave written informed
consent. Patients were randomized to two treatment arms (exper-
imental arm A and standard arm B). A total of 200 patients were
included in the study (100 for each arm). To minimize the influence
of center-specific parameters randomization was performed per
center.
All macroscopically affected tumor sites were treated up to an
equivalent dose at fractionation of 2 Gy (EQD2Gy) of 70 Gy. Frac-
tionation schedule and total dose delivered to the primary tumor
and affected lymph nodes were left to the discretion of each indi-
vidual center. An overview of the different fractionation schedules
and CTV–PTV margins can be found in the preliminary analysis of
this study [10]. For the elective nodal volumes, patients random-
ized in arm A (experimental arm) were treated up to a EQD2Gy
of 40 Gy. For arm B (control arm) the elective nodal volumes were
treated up to a EQD2Gy of 50 Gy [10].
The endpoint of the current study is fibrosis RTOG2-4 at
6 months of follow up. Patients from the original trial lacking tox-
icity scores at 6 months following the end of RT (32 patients) were
excluded from the current analysis. A cohort of 161 patients (of the
original 193 patients) remained available for further analysis.
All patients were treated with intensity modulated radiother-
apy (IMRT). For target volume definition, a planning CT scan was
used. The Planning Target Volume (PTV) was cropped for the outer
contours of the patient (body). Chemotherapy consisted of cis-
platin 100 mg/m2 three weekly or cisplatin 40 mg/m2 weekly.2c 34/161 (21.1%)
3 3/161 (1.9%)
Primary tumor site
Oral cavity 17/161 (10.6%)
Oropharynx 72/161 (44.7%)
HPV + 15/72
HPV  51/72
Unknown HPV status 6/72
Hypopharynx 36/161 (22.4%)
Larynx 28/161 (17.4%)
CUP 8/161 (5.0%)
Sex
Male 132/161 (82.0%)
Female 29/161 (18.0%)
Age at diagnosis
Mean 59.5
Median 58.0
Range (39.0; 81.0)
Drinks/week
Mean 26.0
Median 15.0
Range (0.0; 300.0)
Pack years
Mean 34.3
Median 35.0
Range (0.0; 104.0)
UICC anatomical stage groups
I 0 (0%)
II 18 (11.2%)
III 37 (23.0%)
IV 105 (65.8%)
ND = neck dissection, CUP = cancer of unknown primary, HPV = human papilloma
virus.
x For one patient, no information regarding smoking and alcohol use.Toxicity scoring and statistical analysis
Early toxicity was scored prospectively using the CTCAE criteria
(version 3.0), late toxicity was scored prospectively by the physi-
cian using the RTOG-EORTC late radiation morbidity scoring.
We tested age, sex, T/N stage, tumor site, concomitant
chemotherapy, upfront neck dissection, neo-adjuvant chemother-
apy, accelerated RT, HPV status, smoking (never-former-current),
pack years, alcohol consumption (never-former-current), drinks/
week the dose prescribed to the elective neck, HPV status and
radiodermatitis (grade 0–2 versus grade 3–4) at the end of treat-
ment for their potential to predict neck fibrosis RTOG2-4 6 months
after the end of treatment. No patients underwent adjuvant sur-
gery, besides the patients who underwent an upfront neck dissec-
tion. Since only 4 patients never smoked, we made a group of
patients who never smoked or smoked in the past to use for the
further statistical analysis.
Fisher’s exact test and Mann–Whitney U test were used for test-
ing the association between fibrosis (grade 0–1 versus grade 2–4)
with categorical or continuous variables, respectively. A stepwise
selection procedure was followed to determine the best combina-
tion of predictor variables for fibrosis RTOG2-4 at 6 months. The
Area under the ROC curve (AUC) was determined for the final
model. Additionally a bootstrap-corrected AUC value was calcu-
lated. This AUC value corrects for over optimism resulting from
the fact that model construction and model validation were per-
formed on the same data set. All tests are two-sided, a 5% signifi-
cance level is considered for all tests. Analyses have been
performed using SAS software (version 9.4 of the SAS System for
Windows).Please cite this article in press as: Nevens D et al. Radiotherapy induced dermat
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The pre-treatment characteristics of these 161 patients are
listed in Table 1. Different RT schedules were applied according
to the policies of the individual treatment centers (Supplementaryitis is a strong predictor for late fibrosis in head and neck cancer. The devel-
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ule was administered in 49 patients. A total dose of 72 Gy was
delivered in an overall treatment time of 6 weeks. Concomitant
CRT was used in 113 patients.
The incidences of radiodermatitis at the end of treatment and
fibrosis at 6 months of follow-up are presented in the Supplemen-
tary data Table 2. Severe early and late skin toxicity are observed in
about 24.1% and 29.2% respectively.
Upfront neck dissection (p < 0.01), radiodermatitis at the end of
R(C)TPgrade 3 (p < 0.01), increasing N stage (p < 0.01) and tumor
subsite (p = 0.02) are significantly associated with the incidence of
fibrosis RTOG2-4 at 6 months in our patient population according to
univariate analysis (Table 2). Fig. 1 presents the estimated proba-
bility (with 95% confidence intervals) of severe fibrosis for 3 levels
of early skin toxicity.
Concomitant chemotherapy (p = 0.85), neo-adjuvant
chemotherapy (p = 0.36), hyperfractionated RT (p = 1.00), smoking
(p = 1.00), pack years (p = 0.23), alcohol consumption (p = 0.88),
drinks/week (p = 0.39), T stage (p = 0.59), HPV status (p = 0.85),
sex (p = 0.50), age (p = 0.13) and dose to the elective neck (40 Gy
versus 50 Gy, p = 0.86) were not associated with the incidence of
fibrosis RTOG2-4.
Upfront neck dissection (p < 0.01) and radiodermatitis
gradeP 3 (p < 0.01) at the end of R(C)T were identified for the
model. Additionally, increasing N stage was selected as an inde-
pendent predictor variable (p = 0.04) (Table 3). The AUC for this
model containing upfront neck dissection, erythema at the end of
treatment and increasing N stage was 0.92 (95% CI 0.87;0.96);
the bootstrap-corrected AUC was 0.90 (95%CI 0.85;0.94).
The risk for fibrosis RTOG2-4 at 6 months can be calculated using
the following formula:
Risk for fibrosis RTOG2 4 at 6 months ¼ e
l
1þ el
l¼5:3225
þ5:0693 ðonly when upfront neck dissectionwas performedÞ
þ4:8612 ðwhen gradeP3 radiodermatitis at the end of treatmentÞ
þ0:3691Nstage ðN0¼0; N1¼1; N2a¼2; N2b¼3; N2c¼4; N3¼5Þ
Furthermore, we investigated if the model performs better if the
grade of dermatitis is included (0–1–2–3–4), instead of only
including a distinction between grade 0–2 or higher. The AUC for
the model with the actual grade instead of the distinction between
grade 0–2 or higher is 0.91. Changing the binary score with the
grade of radiodermatitis does not make the model more
performant.Table 2
Statistically significant associations between the patient parameters and the
incidence of fibrosis RTOG2-4 at 6 months, after univariate analysis. G = grade,
CUP = cancer of unknown primary, ND = neck dissection.
Variable Fibrosis G0-1 Fibrosis G2-4 p value
No upfront ND 104/127 (81.9%) 23/127 (18.1%) p < 0.01
Upfront ND 10/34 (29.4%) 24/34 (70.6%)
Radiodermatitis G0-2 100/122 (82.0%) 22/122 (18.0%) p < 0.01
Radiodermatitis G3-4 14/39 (35.9%) 25/39 (64.1%)
N0 38/40 (95.0%) 2/40 (5.0%) p < 0.01
N1 17/23 (73.9%) 6/23 (26.1%)
N2a 4/6 (66.7%) 2/6 (33.3%)
N2b 35/55 (63.6%) 20/55 (36.4%)
N2c 19/34 (55.9%) 15/34 (44.1%)
N3 1/3 (33.3%) 2/3 (66.7%)
Oral cavity 11/17 (64.7%) 6/17 (35.3%) p = 0.017
Oropharynx 54/72 (75.0%) 18/72 (25.0%)
Hypopharynx 23/36 (63.9%) 13/36 (36.1%)
Larynx 24/28 (85.7%) 4/28 (14.3%)
CUP 2/8 (25.0%) 6/8 (75.0%)
Please cite this article in press as: Nevens D et al. Radiotherapy induced dermati
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N-stages according to the 2 other variables of the model.Discussion
Neck fibrosis is a late complication following R(C)T for HNC that
negatively affects QoL. Since the treatment options for fibrosis fol-
lowing RT for HNC are currently limited, the focus lies on preven-
tion. A first step in searching for possibilities of prevention of
mitigation resides in the identification of patient and treatment
related parameters associated with late fibrosis. A previous model
for fibrosis, based on retrospective data, selected a high dose to a
4.1-mm depth of the skin and upfront neck dissection as risk fac-
tors for moderate to severe subcutaneous fibrosis after whole neck
irradiation [7].
We hypothesized that early radiodermatitis was associated
with late fibrosis either due to a different sensitivity to RT between
patients for both early and late toxicity or due to consequential late
toxicity caused by early toxicity. As a matter of principle, the rela-
tionship between increased early toxicity and late dysphagia has
been demonstrated in the past [11].
This hypothesis has been confirmed by our findings. Following
univariate analysis, we detected upfront neck dissection, radioder-
matitis at the end of R(C)TPgrade 3, increasing N stage and tumor
subsite as being significantly associated with fibrosis RTOG2-4 at
6 months. Upfront neck dissection and radiodermatitis gradeP 3
at the end of R(C)T were identified by our multivariate model.
Additionally, increasing N stage was selected. For example, using
our model, a patient who received an upfront neck dissection for
a nodal N2c stage head and neck tumor and suffered from radio-
dermatitis grade 2 at the end of radiotherapy, has a risk of develop-
ing fibrosis RTOG2-4 at 6 months of 77.26%.
The fact that tumor location was not selected by our multivari-
able model can be explained by the observation that almost all
patients with CUP received an upfront neck dissection. CUP was
significantly associated with fibrosis RTOG2-4 at 6 months follow-
ing univariate analysis.
The question arises if we can prevent fibrosis by changing
parameters that were selected by our multivariate model. Avoiding
upfront neck dissections, the first factor of our model, seems a way
to limit the incidence of fibrosis RTOG2-4 at 6 months. The influ-
ence of upfront neck dissection on late fibrosis was already
described by Hirota et al. [7]. The need for upfront ND in the treat-
ment of HNC is still a matter of debate. Recently, a systematic
review on the subject concluded that few comparative studies
suggest possible benefits of upfront neck dissection in the RT
organ-preserving setting in terms of early toxicity and oncological
outcome, although the level of evidence is very low [12]. Most
studies on this subject have a low number of patients, do not
contain information on HPV status and date from an era before
concomitant CT treatment was common. Larger comparative stud-
ies that include HPV status and concomitant CT and randomized
controlled trials are needed in this setting to evaluate the necessity
of upfront ND [11]. The effect of adjuvant neck dissection could not
be assessed in the current study since none of the patients received
a neck dissection following RT.
Another way to limit the incidence of fibrosis RTOG2-4 might
reside in the prevention of radiodermatitis at the end of R(C)T
Pgrade 3, the second factor of our model, as much as possible, since
we clearly demonstrated that this early side effect has repercus-
sions on the incidence of late fibrosis. The relationship between
early and late side effects was recently demonstrated for dysphagia
[11]. A recent review found no strong evidence of effect for any
topical products in reducing radiodermatitis [13]. The MASCC Skin
Toxicity Study Group developed radiodermatitis prevention andtis is a strong predictor for late fibrosis in head and neck cancer. The devel-
x.doi.org/10.1016/j.radonc.2016.08.013
Fig. 1. presents the estimated probability (with 95% confidence intervals) of severe fibrosis for 3 levels of early skin toxicity. There were only 4 patients with grade 0, who
were excluded for this analysis.
Table 3
Multivariable model with the selected variables and the corresponding odds ratios (OR) with 95% confidence intervals.
Variable OR p-Value
LN dissection vs No LN dissection 159.06 (19.158;1320.7) <0.001
Severe toxicity (P3) vs No/mild toxicity (0–2) 129.18 (15.930;1047.6) <0.001
N-stage (+1 level) 1.446 (1.012;2.068) 0.043
Binary variables: OR>(<)1 means higher (lower) risk for first category.
Continuous/ordinal variables: OR>(<)1 means higher (lower) risk for higher level.
Table 4
Predicted severe fibrosis risk by patient characteristics.
Neck dissection (ND) Radiodermatitis N-stage Predicted risk
No ND Grade (0–2) 0 0.005
1 0.007
2b 0.015
2c 0.021
Grade (3) 0 0.387
1 0.477
2b 0.656
2c 0.734
ND Grade (0–2) 0 0.437
1 0.529
2b 0.701
2c 0.773
Grade (3) 0 0.990
1 0.993
2b 0.997
2c 0.998
4 A predictive model for fibrosis in head and neck cancertreatment guidelines based on evidence from randomized, con-
trolled trials. The adoption of washing with water, with or without
a mild soap, and allowing the use of antiperspirants is supported
by randomized trials. There is some evidence that silver sulfadi-
azine cream can reduce dermatitis score [14].
Another possibility to limit the incidence of early radiodermati-
tis besides topical products is the use of new RT techniques such as
proton RT [15] or adaptation of the treatment, in order to limit the
dose to the neck as much as possible, when patients experience
more than average early symptoms [11]. This can be done by using
adaptive replanning or by changing to other treatment modalities
such as proton planning where available in case of more thanPlease cite this article in press as: Nevens D et al. Radiotherapy induced dermat
opment of a predictive model for late fibrosis. Radiother Oncol (2016), http://daverage early toxicity [11]. These kind of tailored treatment adjust-
ments based on early symptom profiles may be worthwhile to
investigate in future clinical studies [11]. Furthermore, in the
future, genetic analysis could help us to select patients who are
more at risk for early toxicity like radiodermatitis. Selection of
these patients before treatment harbors the potential to adapt
and individualize their treatment in order to limit early dermatitis
and late fibrosis. Polymorphism near the LIG3 gene, for example, is
associated with early skin toxicity following RT [16].
The selection of the third factor of our multivariate model,
increasing N stage, might be due to the fact that in more advanced
nodal stages the surrounding soft tissues and skin receive a higher
RT dose, since the pathological lymph nodes are larger and are
more likely to be in close contact with the skin. However we can-
not confirm this interaction with our current data. We found no
difference between administering a EQD2Gy of 40 Gy versus
50 Gy to the elective neck in terms of late fibrosis. This could be
explained by the theory that the curative doses to pathological
lymph nodes have more impact on radiodermatitis and late fibrosis
than the dose to the elective nodal volume. This theory originates
out of the observation that increased N stage is selected for our
model but administering a EQD2Gy of 40 Gy versus 50 Gy to the
elective neck was not.
Apart from avoiding the factors that were selected for our
model as much as possible in order to limit late fibrosis, our model
could be of use for future studies looking at treatment options for
patients facing fibrosis. For these studies, it is important to be able
to select potential patients in an early stage. Treatment options like
stretching exercises and prophylactic swallowing exercises are
very time-consuming and less likely to be used on the long term
in a less than average compliant population [9].itis is a strong predictor for late fibrosis in head and neck cancer. The devel-
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referred to as Concordance index and bears the following interpre-
tation: a model with perfect discrimination would have an index of
1, whereas a value of 0.5 indicates that a coin toss would provide
information as accurate as that given by the model. Because we
have no external validation of our model, additionally a
bootstrap-corrected AUC value is presented. This AUC value cor-
rects for overoptimism resulting from model construction and
model validation that were performed on the same data set. The
corrected AUC gives an honest estimate of predictive accuracy of
the model if it would be applied to an independent sample [17].
The fact that diabetes and skin diseases (such as scleroderma)
were not assessed in our patient population is a limitation. We
did not take this into account in the analysis of this study because
we did not screen for these factors at inclusion of the randomized
trial [10]. On the other hand, the strength of this paper lies in the
fact that all data were prospectively gathered and that this is the
first paper to demonstrate a link between radiodermatitis and late
fibrosis.
A model for the prediction of fibrosis RTOG2-4 following R(C)T
for HNC is presented with an AUC of 0.92. A bootstrap-correction
was performed because we were not able to externally validate
our results. Interestingly radiodermatitis at the end of R(C)T is
associated with RTOG2-4 fibrosis at 6 months in our patient popu-
lation. Attempts should be undertaken to decrease radiodermatitis
in order to decrease late fibrosis
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